New Approaches to Investigate Novel Agents in Ewing Sarcoma: A Report From the Children's Oncology Group Bone Tumor Committee

Outcomes for relapsed Ewing sarcoma remain consistently poor. Continued efforts to consider creative new approaches for the treatment of relapsed Ewing sarcoma are needed. The Children's Oncology Group Bone Tumor Committee convened a New Strategies for Ewing Sarcoma Task Force to systematically evaluate agents for inclusion in future Phase II or III clinical trials for relapsed Ewing sarcoma. In addition, the Task Force summarized the possible limitations of common trial designs and considered new approaches to study promising agents in clinical trials. Here, we summarize this work and propose next steps for future trials for relapsed Ewing sarcoma.